These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26379080)

  • 1. Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma.
    Rossi L; Laas E; Mallon P; Vincent-Salomon A; Guinebretiere JM; Lerebours F; Rouzier R; Pierga JY; Reyal F
    Br J Cancer; 2015 Sep; 113(7):996-1002. PubMed ID: 26379080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
    Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
    Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
    Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
    Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
    J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women.
    Kim J; Han W; Jung SY; Park YH; Moon HG; Ahn SK; Lee JW; Kim MK; Kim JJ; Lee ES; You TK; Kang HS; Lee ES; Ro J; Lee JE; Nam SJ; Yim YH; Park IA; Noh DY
    Ann Surg Oncol; 2015 Oct; 22(11):3481-8. PubMed ID: 25652052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential utility of geminin as a predictive biomarker in breast cancer.
    Sundara Rajan S; Hanby AM; Horgan K; Thygesen HH; Speirs V
    Breast Cancer Res Treat; 2014 Jan; 143(1):91-8. PubMed ID: 24292956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
    Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
    J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantum dot-based multispectral fluorescent imaging to quantitatively study co-expressions of Ki67 and HER2 in breast cancer.
    Xiang QM; Wang LW; Yuan JP; Chen JM; Yang F; Li Y
    Exp Mol Pathol; 2015 Aug; 99(1):133-8. PubMed ID: 26102249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.
    Synnestvedt M; Borgen E; Russnes HG; Kumar NT; Schlichting E; Giercksky KE; Kåresen R; Nesland JM; Naume B
    Acta Oncol; 2013 Jan; 52(1):91-101. PubMed ID: 22934555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index.
    Jalava P; Kuopio T; Juntti-Patinen L; Kotkansalo T; Kronqvist P; Collan Y
    Histopathology; 2006 May; 48(6):674-82. PubMed ID: 16681683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
    Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
    Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
    Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
    Zurrida S; Bagnardi V; Curigliano G; Mastropasqua MG; Orecchia R; Disalvatore D; Greco M; Cataliotti L; D'Aiuto G; Talakhadze N; Goldhirsch A; Viale G
    Eur J Cancer; 2013 Oct; 49(15):3083-92. PubMed ID: 23777741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
    Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
    Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.